Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
The program will provide funding and expertise to clinics in low-income countries to run methylation array-based assays to classify central nervous system tumors in children.
The grants include a two-year $2 million SBIR award from the National Cancer Institute and a $500,000 grant from Washington's Andy Hill Care Fund.
Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.
The team has received a $1.5 million US Department of Defense grant to help launch its project on diffuse B-cell lymphoma resistance to CAR T-cell therapy.
Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.
The firm isn't planning a strategy for a kitted version of the test, though company officials said they were open to that in the future.
The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.
Labs should not let in silico data supplant physical specimens in bioinformatic validation and should understand the limitations of such data.
The company saw strong uptake of its sequencing platforms in the clinical oncology market, a trend that is projected to continue in 2022.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.